In-vivo imaging of cellular proliferation in renal cell carcinoma using 18F-Fluorothymidine (FLT) PET
- Dr Sze Ting Lee, Centre for PET; Ludwig Institute for Cancer Research; Department of Medicine, University of Melbourne, Austin Hospital, Vic, Australia
|
Dual-time point 18F-FDG PET imaging in suspected malignancy
- Dr Wai-Ling Chan, St Vincent's Hospital, Sydney, Australia
|
Correlation of 11C-Choline PET, histopathology and PSA levels in prostate cancer patients undergoing neoadjuvant docetaxel chemotherapy
- Dr Sze Ting Lee, Centre for PET, Ludwig Institute for Cancer Research, Department of Medicine, Austin Hospital, Victoria, Australia
|
Early Experience with FLT PET for Response Assessment in Malignant Pleural Mesothelioma (MPM)
- Dr Roslyn J Francis, Sir Charles Gairdner Hospital, Australia
|
The Accuracy of registration of 18FDG PET-CT to radiotherapy planning CT for Non Small Cell Lung Cancer
- Dr Mei Ling Yap, Radiation Oncology Department, Liverpool Hospital, Australia
|
PET/CT Staging of T1-Stage Non-Small Cell Lung Cancer
- Dr Khalid A Salman, University Hospital of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland, Switzerland
|
FDG PET in monitoring response to neoadjuvant chemoradiotherapy in patients with locally advanced non-small lung carcinoma
- Dr Salvatore U Berlangieri, Austin Health, Australia
|
